The First Epiretinal Implant for Hereditary Blindness in the Asia-Pacific Region

• Published in: Hawai'i journal of health & social welfare 2021-11, Vol.80 (11 Suppl 3), p.10-15
• Main Authors: Yanagihara, Ryan T, Yamane, Maya L M, Kokame, Gregg T
• Format: Article
• Language: English
• Subjects: Aged; Asia; Blindness - surgery; Female; Humans; Retinitis Pigmentosa - genetics; Retinitis Pigmentosa - surgery; Visual Prosthesis
• ISSN: 2641-5216; 2641-5224

In February 2013, the Argus® II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, CA, US) became the first "bionic eye" approved by the FDA to restore useful vision in patients previously blinded by end-stage retinitis pigmentosa, a hereditary, progressive degeneration of the outer retinal photoreceptor cells. The system captures and converts an external optical input into an electrical signal that activates an epiretinal electrode array on the inner surface of the retina. This signal bypasses dysfunctional photoreceptors and directly stimulates the functional inner retina, thus transmitting information to the visual cortex and creating artificial vision. This article describes the first implantation of the Argus II Retinal Prosthesis System in the Asia-Pacific region, which occurred in a deaf and blind 72-year-old Japanese American woman with Usher syndrome. At 57 months after her operation, the patient uses the device daily to perform visual tasks, and the microelectrode array remains in the proper position on the macula. This case demonstrates the long-term safety and efficacy of the Argus II epiretinal implant, which allowed a functionally blind patient to gain meaningful vision.